Nitrosamine Issue Presages Paradigm Shift In Quality
Just How Well Do Companies Know Their Products?
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
You may also be interested in...
A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.
OTC ranitidine products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.
Pharmacy petitions for recalls after finding ‘inherent instability’ in antacid that could pose carcinogenic risk.